News Search Results
Feb 13, 2026, 01:04 ET HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration
More news about: HanchorBio Inc.
Feb 12, 2026, 16:05 ET Vasa Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference
Calif. and WROCLAW, Poland, Feb. 12, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced its participation at the 36th Annual Oppenheimer
More news about: Vasa Therapeutics
Feb 12, 2026, 16:05 ET BioMarin Announces Closing of Private Offering of Senior Notes
securities in any jurisdiction in contravention of applicable law.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Feb 12, 2026, 14:15 ET Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
[email protected]. UNIQURE N.V. CLASS ACTION LAWSUIT COMPLAINT ALLEGEGATIONS uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease ("HD"). uniQure is incorporated in The Netherlands with its
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 12, 2026, 10:45 ET Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced that the first participants
More news about: Centivax
Feb 12, 2026, 10:00 ET Yosemite Announces More Than $18 Million Deployed in Grants
example included preclinical research led by Craig Crews at Yale, which contributed to foundational insights behind the formation of Quarry Thera, a biotechnology company developing small molecule drugs that modulate protein interactions in completely novel ways to treat cancer and autoimmune diseases.Collaboration
More news about: Yosemite
Feb 12, 2026, 09:30 ET Timken Awards Scholarships Valued at up to $540,000 to 20 Students Around the World
Sylwester Struski and Edyta Struska from Czeladź, Poland. She plans to study medicine at the Medical University of Wrocław, specializing in surgery or biotechnology.Lana Mary Tom, daughter of senior system consultant Tom Chandy and Jyothi Jose from Christ Junior College in Bangalore, India. She
More news about: The Timken Company
Feb 12, 2026, 09:00 ET Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide
advancing toward the automated future of "lights-out laboratories."The industry widely recognizes that the deep integration of AI technology and biotechnology represents a key direction for the future of pharmaceutical R&D. In response, Sanyou Biopharmaceuticals is committed to building an intelligent
More news about: Sanyou Bio
Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 12, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Feb 12, 2026, 08:00 ET Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers
—NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced the launch of Open Aperture, a material transfer
More news about: Apertura Gene Therapy
Feb 12, 2026, 07:30 ET Soligenix Details Recent Progress and Upcoming Milestones
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Feb 12, 2026, 06:59 ET Microbiology Testing Market worth $10.09 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187005691 Microbiology testing is widely used across pharmaceutical manufacturing, biotechnology, food and beverage processing, water quality monitoring, and environmental applications. Market expansion is driven by rising demand for contamination
More news about: MarketsandMarkets
Feb 11, 2026, 23:18 ET Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
more effective and better-tolerated treatment options for patients living with IPF.About ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, the company
More news about: Arkbio
Feb 11, 2026, 23:18 ET Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
more effective and better-tolerated treatment options for patients living with IPF.About ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, the company
More news about: Arkbio
Feb 11, 2026, 22:23 ET Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten
More news about: Nektar Therapeutics
Feb 11, 2026, 20:00 ET ToolGen Enters 'Harvest Season' for Global IP Monetization; Appoints Litigation & Negotiation Expert Dave Koo as CLO
Associate at Baker & McKenzie and Paul HastingsLed victories and high-value settlements in major patent disputes among global ICT and biotechnology leaders, including semiconductors, displays, and next-generation light source technologies.Admissions Member
More news about: ToolGen
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Bayer, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, Taiho Oncology, BeOne Medicines (formerly BeiGene), Ono Pharmaceutical, Avistone Biotechnology, Dizal Pharmaceuticals, Checkpoint Therapeutics, DEKA Biosciences, and Taiho Oncology among others.
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 12:27 ET Jennifer Laucirica Named Co-Chair of Trusts & Estates Department at Rubin Rudman
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Feb 11, 2026, 12:16 ET Trescal Reaffirms Dominance in Calibration Sector
coast: Silicon Valley, California, and Melbourne, Florida.Silicon Valley laboratory is tailored to the rigorous compliance needs of the biotechnology, pharmaceutical, and medical device sectors. It offers ISO 17025 accredited services specifically for the instrumentation critical to GxP environments,
More news about: Trescal
Feb 11, 2026, 10:50 ET Genomics Market to Reach $97.1 Billion by 2033 Globally, at 11.5% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/connect-to-analyst/5474The pharmaceutical and biotechnology companies segment generated the highest revenue in 2023By end user, pharmaceutical and biotechnology companies accounted for the largest revenue share in 2023. These companies extensively utilize
More news about: Allied Market Research
Feb 11, 2026, 09:00 ET Decoy Therapeutics Joins Webull Corporate Connect Service Platform
https://www.webullcorp.com/About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Feb 11, 2026, 08:43 ET Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced the completion of its corporate name
More news about: AVAI Bio Inc.
Feb 11, 2026, 08:00 ET Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug
More news about: Evogene; Systasy; LMU University Hospital Munich